查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球糖尿病視網膜病變市場
市場調查報告書
商品編碼
1166532

2022-2029 年全球糖尿病視網膜病變市場

Global Diabetic Retinopathy Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

糖尿病會損害視網膜中的血管，稱為糖尿病性視網膜病變 (DR)。 這種疾病有兩種類型：非增殖性 DR 和增殖性或進行性 DR。 它是由於血糖水平的變化導致眼睛中感光組織異常生長引起的。 可能會出現視力模糊、視力不規則、色覺喪失，甚至視力下降。 治療選擇包括眼內類固醇注射、激光手術和玻璃體切除術。 也可通過熒光素血管造影、光學相干斷層掃描等檢查確診。

市場動態

糖尿病患病率上升、糖尿病相關失明發生率上升以及眼科手術和診斷設備技術進步導致糖尿病視網膜病變將在預測期內推動市場。這是一個因素。

糖尿病視網膜病變診斷技術的進步有望推動市場增長。

Retina Labs 是糖尿病視網膜病變和其他眼病遠程視網膜篩查的先驅。 iVision 遠程眼科平台託管在雲端，提供了一個綜合解決方案，結合了先進的眼部成像、臨床解釋和報告工具以及電子轉診。 iVision 是一個遠程眼科平台，專為希望縮小糖尿病眼病護理差距、改善結果和降低成本的醫療保健系統、初級保健提供者和醫療保健計劃而設計。 因此，預計上述因素將在預測期內推動市場。

與糖尿病視網膜病變藥物相關的副作用預計會阻礙市場增長。

Lucentis（雷珠單抗）的嚴重副作用包括眼內感染、白內障和視網膜脫離，這會導致視力模糊、光敏感和視力模糊。 此外，一些患者在註射前後眼壓升高。 此外，還可能發生與血栓相關的致命問題，例如心髒病發作和中風。 致命事件很少見，死因是晚期糖尿病並發症患者的典型死因。 因此，預計上述因素將在預測期內阻礙市場。

COVID-19 影響分析

COVID-19 對糖尿病視網膜病變 (DR) 市場產生了負面影響。 根據國際防盲機構 (IAPB) 2021 年報告，無論地點或組織類型如何，每個人基本上都會受到影響。 至少 60% 的 DR 計劃的預算被削減或完全放棄。 DR 服務的變化將對患有多種疾病的老年患者產生最大的影響。 地處偏遠和社會經濟地位低下對服務可及性的下降有很大影響。 受影響最大的還有各級醫療保健專業人員。 購買工具和藥品的新障礙、不斷變化的目標和相關報告帶來的行政負擔增加，以及為改善眼部健康的努力獲得資金的難度增加，也對市場產生了影響。

此外，作為維持服務的策略，遠程眼科和患者管理系統的引入、任務轉移可能很複雜但對提供有彈性的服務和非面對面的溝通渠道很重要。增加對 因此，上述因素影響了市場，並有望在預測期內有所改善。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 糖尿病視網膜病變診斷技術的進步有望推動市場增長
    • 約束因素
      • 與糖尿病視網膜病變藥物相關的副作用預計會阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 搬運工的五種力量
  • 供應鏈
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按適應症類型

  • 非增殖性糖尿病視網膜病變
  • 增生性糖尿病視網膜病變

第 8 章按藥物類型分類

  • 抗血管內皮生長因子 (VEGF) 製劑
    • 雷珠單抗（Lucentis）
    • 阿柏西普玻璃體內註射 (Eylea)
    • 其他
  • 類固醇眼內註射
  • 激光手術
  • 玻璃體手術
  • 其他

第 9 章最終用戶

  • 最終用戶
    • 醫院
    • 眼科診所
    • 門診手術中心
    • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 競爭場景
  • 市場情況/份額分析
  • 併購分析

第12章公司簡介

  • Abbott Laboratories
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Alimera Science
  • Allergan plc
  • Ampio Pharmaceuticals.
  • Bayer AG
  • Hoffmann-La Roche
  • Novartis International AG
  • Glycadia Pharmaceuticals
  • Regeneron Pharmaceuticals Inc.
  • Valeant Pharmaceutical

第13章 全球糖尿病性視網膜病變市場 - DataM

簡介目錄
Product Code: DMPH29

Market Overview

Diabetes mellitus harms the retina's blood vessels, referred to as diabetic retinopathy (DR). There are two different types of this condition: non-proliferative DR and proliferative or advanced DR. It is brought on by changes in blood glucose levels, which cause the light-sensitive tissues in the eye to grow abnormally. Dark spots or floating strings can be seen in the field of vision, along with blurred or erratic vision, reduced color perception, and even loss of vision. Treatment options include intraocular steroid injection, laser surgery, and vitrectomy. It can be diagnosed using tests like fluorescein angiography and optical coherence tomography.

Market Dynamics

The increasing prevalence of diabetes, rising incidence of diabetes-related blindness, and technological advancements in ophthalmic surgical and diagnostic instruments will enable diabetic retinopathy are the factors to drive the market in the forecast period.

Technological advancement in diagnosing diabetic retinopathy is expected to drive market growth.

Retina Labs has pioneered teleretinal screening for diabetic retinopathy and other ocular disorders. The iVision teleophthalmology platform, hosted in the cloud, provides an integrated solution that combines advanced ocular imaging, clinical interpretation and reporting tools, and electronic referrals. The company's solutions enable healthcare providers to improve access to high-quality eye care while streamlining processes for managing chronic eye diseases such as diabetic retinopathy, glaucoma, age-related macular degeneration, and retinopathy of prematurity. iVision is a teleophthalmology platform designed for health systems, primary care providers, and health plans looking to close care gaps in diabetic eye disease, improve outcomes, and lower costs. Thus, from the above factors, the market is expected to drive in the forecast period.

Side effects associated with the drugs treating diabetic retinopathy are expected to hamper the market growth.

The serious side effects of the LUCENTIS (ranibizumab) drug include infections inside the eye, cataracts, and detached retinas, which can cause blurry vision, light sensitivity, and cloudy vision. Some patients have experienced increased eye pressure before and after injection-moreover, sometimes fatal, blood clot-related problems, such as heart attacks or strokes. Although there were only a few fatal events, the causes of death were typical of patients with advanced diabetic complications. Thus, from the above factors, the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

COVID-19 impacted the diabetic retinopathy(DR) market negatively. According to the International Agency for the Prevention of Blindness (IAPB) report 2021, everybody was essentially affected, regardless of their location or type of organization. At least 60% of DR initiatives had their budgets cut or were completely abandoned. Changes in DR services have the biggest effects on elderly patients with multiple diseases. Reduced access to services is significantly impacted by remoteness and low socioeconomic status. The most impacted individuals are also all levels of healthcare professionals. The market is also affected by new obstacles related to the purchase of tools and medications, a rise in the administrative burden brought on by shifting targets and associated reporting, and growing difficulty in securing funding for initiatives to improve eye health.

Furthermore, the introduction of teleophthalmology and patient flow management were common strategies to retain services, as was task shifting, which was complex but potentially important in providing resilient services, and increased reliance on non-face-to-face communication channels. Thus, from the above factors, the market got affected and is expected to improve in the forecast period.

Segment Analysis

Laser Surgery segment is expected to hold the largest market share in diabetic retinopathy

The laser surgery segment accounted for the largest market share in 2021. Laser treatment usually works well to prevent vision loss before the retina has been severely damaged. Macular edema may benefit as well. This can reduce the swelling of the retina. Laser surgery can also helps in shrinking blood vessels and prevent them from growing again.

Moreover, severe proliferative retinopathy is treated using a more aggressive laser therapy known as scattering (pan-retinal) photocoagulation. It allows doctors to control the spread of new blood vessels across the retina's back. Therefore, there is increased demand for laser surgery for treating diabetic retinopathy. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global diabetic retinopathy market

North America region accounted for the largest market share in 2021. The increasing prevalence of diabetes, the rising geriatric population, increasing FDA approvals in the region and increasing awareness about diabetic retinopathy among people are the factors to drive the market in the forecast period. For instance, according to the IDF Diabetes Atlas 10th Edition, an estimated 51 million adults aged 20-29 were living with diabetes in the IDF NAC region in 2021, representing a regional prevalence of 14.6%. The region has the second-highest number of children and adolescents with type 1 diabetes (193,000).

Additionally, on June 29, 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. FDA has accepted for review the EYLEA (aflibercept) Injection supplemental Biologics License Application (sBLA) for every 16-week 2 mg dosing regimen (after initial monthly doses) in patients with diabetic retinopathy (DR). The target action date for the FDA decision is on February 28, 2023. Thus, from the above-mentioned factors, the North America region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the diabetic retinopathy market are Abbott Laboratories, Alimera Science, Allergan plc, Ampio Pharmaceuticals, Bayer AG, Hoffmann-La Roche, Novartis International AG, Glycadia Pharmaceuticals, Regeneron Pharmaceuticals Inc and Valeant Pharmaceutical.

Regeneron Pharmaceuticals, Inc.:

Overview:

Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Tarrytown in 1988. The company engages in the discovery, invention, development, manufacture, and commercialization of medicines. The biopharmaceutical company develops and manufactures medicines designed to treat a range of illnesses, including asthma, chronic pain, cancer, and infectious diseases. Product portfolio includes the following brands such as EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Product Portfolio:

EYLEA (AFLIBERCEPT) INJECTION: EYLEA is the only vascular endothelial growth factor (VEGF) inhibitor approved with two dosing options for diabetic retinopathy (DR). EYLEA helps in treating all stages of diabetic retinopathy (DR), thereby reducing the risk of blindness.

The global diabetic retinopathy market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancement in diagnosing diabetic retinopathy is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs treating diabetic retinopathy are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Indication Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 7.1.2. Market Attractiveness Index, By Indication Type
  • 7.2. Non-Proliferative Diabetic Retinopathy*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Proliferative Diabetic Retinopathy

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Anti-Vascular Endothelial Growth Factor (VEGF)*
      • 8.2.1.1. Ranibizumab (Lucentis)*
      • 8.2.1.2. Introduction
      • 8.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 8.2.1.4. Aflibercept intravitreal (Eylea)
      • 8.2.1.5. Others
  • 8.3. Intraocular Steroid Injection
  • 8.4. Laser Surgery
  • 8.5. Vitrectomy
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. End user*
      • 9.2.1.1. Hospitals
      • 9.2.1.2. Introduction
      • 9.2.1.3. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
      • 9.2.1.4. Ophthalmic Clinics
      • 9.2.1.5. Ambulatory Surgical Center
      • 9.2.1.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Abbott Laboratories*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Alimera Science
  • 12.3. Allergan plc
  • 12.4. Ampio Pharmaceuticals.
  • 12.5. Bayer AG
  • 12.6. Hoffmann-La Roche
  • 12.7. Novartis International AG
  • 12.8. Glycadia Pharmaceuticals
  • 12.9. Regeneron Pharmaceuticals Inc.
  • 12.10. Valeant Pharmaceutical

LIST NOT EXHAUSTIVE

13. Global Diabetic Retinopathy Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us